BCMA-CD19 car T cell therapy for immune thrombocytopenia with autoimmune diseases
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This trial tests a personalized cell therapy (CAR T cells) that targets two proteins (BCMA and CD19) on immune cells to treat low platelet counts (thrombocytopenia) that haven't improved with other treatments and are linked to autoimmune diseases like lupus or Sjogren's. The goal is to see if this therapy can safely raise your platelet levels and reduce bleeding symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 60 years old.
- You have been diagnosed with immune thrombocytopenia (low platelets) along with an autoimmune disease such as lupus, Sjogren's syndrome, or undifferentiated connective tissue disease.
- Your platelet count is very low (below 30) or if it's between 20 and 30, you have noticeable bleeding symptoms (like easy bruising, bleeding gums, etc.).
- Your kidney function is good (serum creatinine under 2.5 mg/dL).
- You have not had a serious infection recently.
- You are willing to sign the informed consent form after understanding all the risks and benefits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental cell therapy that targets a specific type of immune cell (B cell) to calm the overactive immune response in lupus, which may help reduce symptoms. It is for people with active lupus that has not responded well to other treatments.
This trial tests a new treatment called CAR-T cells that target two proteins (BCMA and CD19) on immune cells. It is for people with certain autoimmune diseases that have not improved with standard treatments.
This study tests an experimental treatment using your own immune cells (called CAR-γδT cells) that target a protein on B cells to calm down autoimmune diseases like lupus, scleroderma, and others. It's for people whose disease hasn't responded to standard treatments, and the goal is to see if it's safe and whether it can reduce disease activity.
This trial tests a personalized cell therapy (CAR-T cells that target CD19 and BCMA proteins) for people with lupus, Sjogren's, scleroderma, dermatomyositis, antisynthetase syndrome, immune-mediated necrotizing myopathy, rheumatoid arthritis, or ANCA-associated vasculitis that has not responded to standard treatments. The goal is to see if this therapy can reduce disease activity.
This trial tests a new treatment using your own immune cells (called CAR-T cells) designed to target and attack cells that cause autoimmune diseases. It is for people with lupus, Sjögren's syndrome, inflammatory myopathy, scleroderma, Behcet's disease, ANCA-associated vasculitis, IgG4-related disease, antiphospholipid syndrome, or thrombotic thrombocytopenic purpura who have not improved with standard therapies.
This trial tests a new CAR-T cell treatment for people with certain autoimmune diseases that have not responded to standard therapies. The treatment uses your own immune cells modified to target and attack disease-causing cells.
Hear when a new Refractory Immune Cytopenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.